Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

Scot A. Niglio(National Cancer Institute), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), John P. Sfakianos(Mount Sinai Medical Center), Reza Mehrazin(Icahn School of Medicine at Mount Sinai), Alberto Martini(The University of Texas MD Anderson Cancer Center), Kathryn E. Marqueen(Icahn School of Medicine at Mount Sinai), Rachel Jia(Icahn School of Medicine at Mount Sinai), Samuel Ruder(NewYork–Presbyterian Hospital), Bart S. Ferket(PragmatIC (United Kingdom)), Madhu Mazumdar(Memorial Sloan Kettering Cancer Center), Vaibhav G. Patel(Arvinas (United States)), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Nikhil Waingankar(Icahn School of Medicine at Mount Sinai), Jiayi Ji(Boston Medical Center), Peter Wiklund(Unknown)
European Urology
June 11, 2019
10.1016/j.eururo.2019.05.037
Cited by 109

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k